Headquartered in Brisbane, CA Fiscal year ends December NASDAQ: VERA veratx.com
Vera Therapeutics is a commercial-stage biotechnology company focused on autoimmune disease, starting with the kidney. Its flagship product is TRUTAKNA (atacicept-vymj), a dual BAFF and APRIL inhibitor. TRUTAKNA is a soluble recombinant TACI-Fc fusion protein, self-administered at home as a once-weekly 150 mg autoinjector. It received FDA accelerated approval on July 7, 2026 to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression, and launched in the U.S. that quarter. The company has filed an sBLA seeking full approval based on the ORIGIN 3 trial and plans a European Marketing Authorisation Application in Q1 2027. It supports patient access through the TRUTAKNA TRU SUPPORT program, which offers insurance assistance and copay support. Through the Phase 2 PIONEER basket trial, Vera is also evaluating atacicept in other antibody-mediated glomerular diseases, including primary membranous nephropathy and pediatric IgAN. Updated
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Vera Therapeutics is a commercial-stage biotechnology company focused on autoimmune disease, starting with the kidney. Its flagship product is TRUTAKNA (atacicept-vymj), a dual BAFF and APRIL inhibitor.
The Wall Street consensus 12-month price target for VERA is $71.93.
